NNVC - NANOVIRICIDES, INC.

1.15
0.178   15.487%

Share volume: 946,033
Last Updated: 03-11-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.16%

PREVIOUS CLOSE
CHG
CHG%
$0.97
0.18
0.18%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
5%
Profitability 0%
Dept financing 4%
Liquidity 50%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
17.35%
1 Month
23.66%
3 Months
-8.00%
6 Months
-20.69%
1 Year
-6.50%
2 Year
1.77%
Key data
Stock price
$1.15
P/E Ratio 
0.00
DAY RANGE
$0.98 - $1.15
EPS 
-$0.49
52 WEEK RANGE
$0.85 - $2.23
52 WEEK CHANGE
-$4.96
MARKET CAP 
20.337 M
YIELD 
N/A
SHARES OUTSTANDING 
21.595 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-14-2025
BETA 
0.36
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$245,328
AVERAGE 30 VOLUME 
$247,590
Company detail
CEO: Anil R. Diwan
Region: US
Website: nanoviricides.com
Employees: 20
IPO year: 2005
Issue type: Common Stock
Market: NYSE American
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

NanoViricides, Inc. discovers, develops, and commercializes drugs for the treatment of viral infections. Company develops Human Coronavirus Program for COVID-19 seasonal coronavirus affliction. Company also develops FluCide Broad-Spectrum Anti-Influenza nanoviricide.

Recent news